-14%

est. 2Y upside i

HealthcareSeries D+

Rank

#3216

Sector

Biotechnology

Est. Liquidity

~3Y

Data Quality

Data: Low

Ultimagenomics offers a disruptive technology in a large market, but the investment is highly speculative due to stale valuation, missing revenue data, and severe preference overhang.

Last updated: July 3, 2026

Bull (10%)+180%

If Ultimagenomics achieves market leadership and IPO, valuation could triple to $3B, net of 20% dilution, yielding 180% upside.

Base (45%)+30%

Steady growth and market share gains lead to 1.5x exit valuation, net of dilution gives 30% upside.

Bear (45%)-100%

Competition from Illumina and capital intensity cause exit below $700M preference stack, resulting in total loss for common stock.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

70%

Total preferred stock ($700M) is 70% of entry valuation ($1B), meaning common shareholders only capture value above $700M exit.

Dilution Risk

high

Given cash burn and lack of recent funding, a significant raise within 24 months is likely, diluting common equity by ~20%.

Secondary Liquidity

none

No secondary market data available; liquidity events likely distant.

Other — 13 roles

View all 13 open roles at Ultimagenomics →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Ultimagenomics's data — designed to show you've done your homework.

  • 1

    “How will Ultimagenomics differentiate and gain market share against Illumina's dominant position?”

  • 2

    “What is the company's path to profitability and how does the recurring consumables model support unit economics?”

  • 3

    “What is the expected timeline for an IPO or acquisition, and how does the equity structure protect common shareholders?”

Community

Valuation Sentiment

Our model estimates -14% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.